Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research  by Burke, Michael J. et al.
Biol Blood Marrow Transplant 21 (2015) 2154e2159Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgTransplant Outcomes for Children with T Cell Acute
Lymphoblastic Leukemia in Second Remission: A Report from
the Center for International Blood and Marrow Transplant
ResearchMichael J. Burke 1,*, Michael R. Verneris 2, Jennifer Le Rademacher 3,4, Wensheng He 3,
Hisham Abdel-Azim 5, Allistair A. Abraham6, Jeffery J. Auletta 7, Mouhab Ayas 8,
Valerie I. Brown 9, Mitchell S. Cairo 10, Ka Wah Chan 11, Miguel A. Diaz Perez 12,
Christopher C. Dvorak 13, R. Maarten Egeler 14, Lamis Eldjerou 15, Haydar Frangoul 16,
Gregory M.T. Guilcher 17, Robert J. Hayashi 18, Ahmed Ibrahim 19, Kimberly A. Kasow 20,
Wing H. Leung 21, Richard F. Olsson 22,23, Michael A. Pulsipher 5, Niketa Shah 24, Nirali N. Shah 25,
Elizabeth Thiel 3, Julie-An Talano 1, Carrie L. Kitko 26
1Division of Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin and Children’s Hospital of Wisconsin,
Milwaukee, WI
2Department of Pediatrics, University of Minnesota, Minneapolis, MN
3CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
4Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI
5Division of Hematology, Oncology and Blood & Marrow Transplantation, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine,
Los Angeles, CA
6Division of Blood and Marrow Transplantation, Center for Cancer and Blood Disorders, Children’s National Medical Center, Washington, DC
7Divisions of Hematology/Oncology, Bone Marrow Transplantation and Infectious Diseases, Nationwide Children’s Hospital, Columbus, OH
8Department of Pediatric Hematology Oncology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
9Division of Pediatric Oncology/Hematology, Department of Pediatrics, Penn State Hershey Children’s Hospital and College of Medicine, Hershey, PA
10Department of Pediatrics, New York Medical College, Valhalla, NY
11Department of Pediatrics, Texas Transplant Institute, San Antonio, TX
12Department of Hematology/Oncology, Hospital Infantil Universitario Nino Jesus, Madrid, Spain
13Department of Pediatrics, University of California San Francisco Medical Center, San Francisco, CA
14Department of Hematology/Oncology, Hospital for Sick Children, Toronto, ON, Canada
15Department of Pediatrics, University of Florida, Gainsville, FL
16Division of Hematology-Oncology, Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN
17 Section of Paediatric Oncology and Blood and Marrow Transplant, Alberta Children’s Hospital, Calgary, AB, Canada
18Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine in St. Louis, St. Louis, MO
19Department of Hematology/Oncology, Makassed General Hospital, Beiruit, Lebanon
20Division of Hematology-Oncology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC
21Division of Bone Marrow Transplantation, St. Jude Children’s Research Hospital, Memphis, TN
22Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden
23Centre for Clinical Research Sörmland, Uppsala University, Uppsala, Sweden
24Division of Hematology/Oncology, Department of Pediatrics, Mayo Clinic Arizona and Phoenix Children’s Hospital, Phoenix, AZ
25 Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NIH), Bethesda, MD
26 Stem Cell Transplant Program, Department of Pediatrics, Vanderbilt University, Nashville, TNFinancial disclosure: See Acknowledgments on page 2159.
* Correspondence and reprint requests: Michael J. Burke, MD, Associate
Professor, Division of Hematology/Oncology/Blood and Marrow Transplant,
Medical College of Wisconsin, Department of Pediatrics, Children’s Hospital
of Wisconsin, MACC Fund Research Center, 8701 Watertown Plank Road,
Milwaukee, WI 53226.
E-mail address: mmburke@mcw.edu (M.J. Burke).
http://dx.doi.org/10.1016/j.bbmt.2015.08.023
1083-8791/ 2015 American Society for Blood and Marrow Transplantation.
M.J. Burke et al. / Biol Blood Marrow Transplant 21 (2015) 2154e2159 2155Article history:
Received 6 July 2015
Accepted 20 August 2015
Key Words:
Pediatric
T-cell ALL
Relapse
Acute lymphoblastic leukemia
Transplantationa b s t r a c t
Survival for children with relapsed T cell acute lymphoblastic leukemia (T-ALL) is poor when treated with
chemotherapy alone, and outcomes after allogeneic hematopoietic cell transplantation (HCT) is not well
described. Two hundred twenty-nine children with T-ALL in second complete remission (CR2) received an
HCT after myeloablative conditioning between 2000 and 2011 and were reported to the Center for In-
ternational Blood and Marrow Transplant Research. Median age was 10 years (range, 2 to 18). Donor
source was umbilical cord blood (26%), matched sibling bone marrow (38%), or unrelated bone marrow/
peripheral blood (36%). Acute (grades II to IV) and chronic graft-versus-host disease occurred in,
respectively, 35% (95% conﬁdence interval [CI], 27% to 45%) and 26% (95% CI, 20% to 33%) of patients.
Transplant-related mortality at day 100 and 3-year relapse rates were 13% (95% CI, 9% to 18%) and 30%
(95% CI, 24% to 37%), respectively. Three-year overall survival and disease-free survival rates were 48%
(95% CI, 41% to 55%) and 46% (95% CI, 39% to 52%), respectively. In multivariate analysis, patients with
bone marrow relapse, with or without concurrent extramedullary relapse before HCT, were most likely to
relapse (hazard ratio, 3.94; P ¼ .005) as compared with isolated extramedullary disease. In conclusion,
HCT for pediatric T-ALL in CR2 demonstrates reasonable and durable outcomes, and consideration for HCT
is warranted.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION METHODS
Each year approximately 3000 children in the United
States are diagnosed with acute lymphoblastic leukemia
(ALL) [1], 10% to 15% with T cell ALL (T-ALL) [2-4]. Historically,
T-ALL portended aworse prognosis comparedwith B cell ALL
(75.2% versus 83.7% 5-year event-free survival [EFS] rates)
[5,6], but treatment with intensive, high-dose, multiagent
chemotherapy resulted in signiﬁcantly improved outcomes
(5-year EFS rates of w80%) [7]. Pediatric ALL trials using a
Berlin-Frankfurt-Munsterebased backbone and/or intensi-
ﬁed therapy with high-dose methotrexate have further
improved outcomes for children with T-ALL but have
plateaued at rates of around 85% EFS [8-12]. In contrast, long-
term survival for patients who relapse and are re-treated
with chemotherapy has been very disappointing, with
>90% of patients dying of disease [13-15]. In a report of 207
children with T-ALL in ﬁrst relapse treated with chemo-
therapy alone, the 10-year EFS rate was only 15% [15].
Therefore, allogeneic hematopoietic cell transplantation
(HCT) has typically been the standard approach for relapsed
pediatric T-ALL.
There are limited data reporting HCT outcomes for chil-
dren with relapsed T-ALL [14,15]. Reported outcomes have
generally been poor with predicted EFS rates < 20% with
either HCT or chemotherapy alone [14-16]. Past analyses
included older treatment eras (1980s and 1990s) with little
data on current HCT outcomes for children with relapsed
T-ALL receiving contemporary treatment strategies. Whether
improvements in the current HCT era (post-2000) have
resulted in improved survival, particularly with enhanced
high-resolution HLA typing [17] and better supportive care
[18], is unclear. Likewise, whether patient-, disease-, or HCT-
related variables impact outcomes in relapsed T-ALL in
children is uncertain.
To address these issues we investigated the outcomes of
229 pediatric patients with relapsed T-ALL who received a
myeloablative HCT in second complete remission (CR2) and
were reported to the Center for International Blood
and Marrow Transplant Research (CIBMTR) between 2000
and 2011. These results comprise the largest HCT cohort re-
ported to date of pediatric patients with relapsed T-ALL in
CR2 and highlight the success of current transplant ap-
proaches that have contributed to the improved outcomes
identiﬁed in this analysis.Patients
Datawere obtained from the CIBMTR, aworking group of more than 500
transplant centers worldwide that provide patient, disease, and transplant
characteristics including outcomes for consecutive transplantations to a
statistical center at the Medical College of Wisconsin or a data coordinating
center at the National Marrow Donor Program. Information regarding pre-
HCT chemotherapy (eg, nelarabine), detailed T-ALL immunophenotyping
(eg, early T cell progenitor T-ALL), or pre-HCT minimal residual disease re-
sults were not collected by the CIBMTR during the era of these patients.
Patients or guardians provided written informed consent for data sub-
mission and research participation in accordance with the Declaration of
Helsinki. The institutional review boards of the Medical College of Wis-
consin and the National Marrow Donor Program approved this study.
Eligibility Criteria
Eligible were patients with T-ALL who were 18 years or younger at the
time of transplant, received a myeloablative conditioning regimen in CR2,
and had an HLA-identical sibling or unrelated donor. Transplantations were
performed between 2000 and 2011. Excluded were patients receiving
transplant with ex vivo T cell depletion or having a predisposing condition
before the diagnosis of T-ALL.
Endpoints
Neutrophil recoverywasdeﬁnedasanabsoluteneutrophil count .5109/L
for 3 consecutive days and platelet recovery as a platelet count> 20 109/L for
7 days without transfusion. Transplant-related mortality (TRM) was deﬁned as
anydeathduring remission, and treatment failurewasacompositeendpoint that
included TRM and relapse. Disease-free survival (DFS)was deﬁned as survival in
continuous CR. Relapse was deﬁned as morphologic recurrence of leukemia at
any site. Grades II to IV acute graft-versus-host-disease (GVHD) and chronic
GVHD were deﬁned using standard criteria [19-21].
Statistical Analysis
The probabilities of neutrophil and platelet recovery, acute and chronic
GVHD [19,20], TRM, and relapse were calculated using the cumulative
incidence function estimator [22,23]. For neutrophil and platelet recovery
and GVHD, death without the event was the competing risk. For TRM,
relapse was the competing event, and for relapse, TRM was the competing
event. DFS and overall survival (OS) were calculated using the Kaplan-Meier
estimator [22,24]. Ninety-ﬁve percent conﬁdence intervals (CIs) were
calculated using log transformation. For OS, death from any cause was
considered an event, and patients surviving at last follow-up were censored.
For DFS, relapse and deathwere considered events, and patients surviving in
remission were censored at last follow-up.
Variables tested in the Cox proportional hazards regression model
included age at HCT (10 versus 11 to 18 years), performance score before
HCT (<80 versus 80), recipient cytomegalovirus (CMV) status (positive
versus negative), interval between diagnosis and transplant (<18 [early]
versus 18 to 36 [intermediate] versus >36 months [late]), graft type (bone
marrow [BM] versus peripheral blood versus cord blood), and
donorerecipient HLA match (HLA matched sibling, HLA matched unrelated,
HLA mismatched unrelated, and not reported). Graph source deﬁned as HLA
Table 1
Patient Characteristics
Characteristic Value
Number of patients 229
Number of centers 99
Median age at transplant, yr (range) 10 (2-18)
5 yr 38 (17)
6-10 yr 66 (29)
11-18 yr 125 (55)
Recipient sex
Male 174 (76)
Female
Performance score before HCT
<80 16 (7)
80-100 199 (87)
Unknown 14 (6)
Median time from diagnosis to transplant,
mo (range)
19 (<1-105)
<18 mo 104 (45)
18-36 mo 77 (34)
>36 mo 47 (21)
Unknown 1 (<1)
Conditioning regimen
TBI þ Cy 183 (80)
TBI þ other 33 (14)
Bu þ Cy 13 (6)
Donorerecipient HLA match*
HLA-identical sibling (including 3 CB) 86 (38)
Matched unrelated BM/PBSCs 27 (12)
Mismatched unrelated BM/PBSCs 20 (9)
Matched UCB 10 (4)
Mismatched UCB 50 (22)
Unrelated BM/PBSCs/CB 36 (16)
HLA match not collected
Unrelated donor BM 15
Unrelated donor PBSCs 4
Unrelated donor CB 17
Recipient CMV status
Negative 72 (31)
Positive 92 (40)
Unknown 65 (28)
Graft type
BM 120 (52)
PBSCs 29 (13)
CB 80 (35)
Received antithymocyte globulin or Campath
No 139 (61)
Yes 76 (33)
Unknown 14 (6)
Year of Transplant
2000-2003 73 (32)
2004-2007 78 (34)
2008-2011 78 (34)
GVHD prophylaxis
CSA þ MTX 94 (41)
CSA þ MMF 31 (14)
CSA  corticosteroids 40 (17)
FK506 þ MMF 7 (3)
FK506 þ MTX 36 (16)
FK506 þ Other 3 (1)
Cy alone 1 (<1)
Unknown 17 (7)
Median follow-up, mo (range) 56 (3-150)
Cy indicates cyclophosphamide; Bu, Busulfan; CB, Cord Blood; PBSCs, Pe-
ripheral Blood Stem Cells; CSA, cyclosporine; MTX, methotrexate; MMF,
Mycophenolate Mofetil; FK506, Tacrolimus.
Values are number of cases with percents in parentheses, unless otherwise
noted.
* Best available HLAmatching information was used for unrelated donors.
For unrelated donor transplantation, donorerecipient HLA match consid-
ered allele-level HLA typing at HLA-A, -B, -C, and -DRB1. For UCB trans-
plantation, HLA matching considered low-resolution match at HLA-A and -B
and allele-level at -DRB1.
Table 2
Additional Patient Characteristics Available for Subset Analysis
Characteristic Value
Number of patients 112
WBC at diagnosis
<100  109/L 44 (39)
100  109/L 47 (42)
Unknown 21 (19)
Extramedullary disease before HCT
No 46 (41)
Yes 65 (58)
Unknown 1 (1)
Median duration of CR1, mo (range) 13 (<1-76)
<18 mo 74 (66)
18-36 mo 17 (15)
>36 mo 15 (13)
CR1 indicates 1st complete remission.
Values are number of cases with percents in parentheses, unless otherwise
noted.
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cells [PBSCs]) and unrelated cord blood (UCB) were also compared. Donors
and recipients were considered matched to each other if all 8/8 of the HLA-A, -B, -C, and -DRB1 loci by high-resolution typing were identical. Recipients
of cord blood transplants were considered matched if 6/6 loci HLA-A and -B
loci (by low level typing) and HLA-DR (by high-resolution typing) were all
identical.
Statistically signiﬁcant prognostic factors were selected using a stepwise
selection procedure. A subset of patients had more detailed disease-speciﬁc
information including WBC count at diagnosis and site of ﬁrst relapse
(n¼ 112). An analysis was conducted to investigate the impact ofWBC count
at initial diagnosis (<100  109/L versus  100  109/L) and site of ﬁrst
relapse (isolated extramedullary site versus isolated BM versus BM with
extramedullary site) on outcomes by adding these variables into the ﬁnal
models grouping patients with unreported WBC counts and site of ﬁrst
relapse into 1 group. The presence of GVHD was evaluated as a time-
dependent covariate. All P values were 2-sided, and P  .05 was consid-
ered to be signiﬁcant. Analyses were performed using SAS version 9.1 (SAS
Institute, Cary, NC).RESULTS
Patient, disease, and transplant characteristics are shown
in Table 1. The median age at HCT was 10 years (range, 2 to
18), and 174 patients (76%) were male. Duration of CR1 is not
routinely collected on CIBMTR forms; therefore, time of
initial diagnosis to transplant was used as a surrogate.
Almost half of the patients (45%) relapsed early and came to
HCT within 18 months of diagnosis (n ¼ 104, 45%), 77 (34%)
were transplanted 18 to 36 months from diagnosis, and 47
(21%) were transplanted > 36 months from diagnosis. One
patient had an unknown time to transplant from initial
diagnosis.
HCT conditioning included total body irradiation (TBI)
and cyclophosphamide in 183 patients (80%), 49 patients
(31%) received TBI > 1300 cGY compared with 108 patients
(69%) whose TBI was<1300 cGY; 59 patients hadmissing TBI
dosing data. Seventy-six patients (33%) received serotherapy
with either alemtuzumab (Campath; Genzyme Corporation)
or antithymocyte globulin. A cyclosporine-based regimen
was the primary GVHD prophylaxis used (72%). Most pa-
tients received HLA-matched sibling BM (n ¼ 86, 38%) fol-
lowed by mismatched UCB (n ¼ 50, 22%), matched (n ¼ 27,
12%) or mismatched (n ¼ 20, 9%) unrelated BM/PBSCs, and
HLA-matched UCB (n ¼ 10, 4%). The remaining 36 patients
did not have HLA-matching reported (unrelated UCB, n ¼ 17;
unrelated BM, n ¼ 15; and unrelated PBSCs, n ¼ 4). Seventy-
three patients (32%) received their HCT between 2000 and
2003, 78 (34%) between 2004 and 2007, and the remaining
78 (34%) during 2008 to 2011.
Patient, disease, and transplant characteristics of the 112
patients with more detailed research level data, including
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Figure 1. (A) Cumulative incidence of TRM was 13% (95% CI, 9% to 18%) at day
100, 21% (95% CI, 16% to 26%) at 1 year, and 24% (95% CI, 18% to 30%) at 3 years.
(B) Probability of DFS at 3 years was 46% (95% CI, 39% to 52%).
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Figure 2. (A) Cumulative incidence of relapse at 3 years for patients with an
isolated extramedullary relapse (central nervous system/testes) was 15% (95%
CI, 5% to 28%) compared with 45% (95% CI, 32% to 58%) for patients with
isolated or combined BM relapse (P < .001). (B) Probability of DFS at 3 years for
patients with an isolated extramedullary relapse (central nervous system/
testes) was 56% (95% CI, 39% to 72%) compared with 35% (95% CI, 23% to 47%)
for patients with isolated or combined BM relapse (P ¼ .05).
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are shown in Table 2. Among these, 47 patients (42%) pre-
sented with an initial WBC count  100  109/L and 65 (58%)
had their ﬁrst relapse involving the BM  extramedullary
disease.
Outcomes
Recovery and GVHD
In univariate analysis the probability of neutrophil
recovery by day 28 was 83% (95% CI, 78% to 88%), and platelet
recovery by day 100 was 76% (95% CI, 70% to 82%). The
incidence of acute GVHD (grades II to IV) by day 100 was 35%
(95% CI, 27% to 45%), and 26% of patients (95% CI, 20% to 33%)
had chronic GVHD by 1 year (limited and extensive).
TRM, relapse, and DFS
TRM at day 100 was 13% (95% CI, 9% to 18%), increasing to
21% (95% CI, 16% to 26%) at 1 year and to 24% (95% CI, 18% to
30%) at 3 years (Figure 1A). The rate of relapse at 3 years was
30% (95% CI, 24% to 37%). Rates of 3-year DFS (Figure 1B) and
OS were 46% (95% CI, 39% to 52%) and 48% (95% CI, 41% to
55%), respectively. Relapse was the most frequent cause of
death (59/116; 51%) in this analysis. Other causes of death
were related to infection (n ¼ 13, 11%), TRM not speciﬁed
(n ¼ 13, 11%), organ failure (n ¼ 10, 9%), idiopathic pneu-
monia syndrome/acute respiratory distress syndrome (n¼ 8,
7%), GVHD (n ¼ 7, 5%), hemorrhage (n ¼ 4, 3%), and graft
failure (n ¼ 2, 2%).
Univariate post-HCT outcomes analyzed included site of
initial relapse (isolated BM/combined BM versus isolatedextramedullary [central nervous system/testes]) and graft
source (HLA identical sibling versus unrelated donor BM/
PBSCs versus UCB). Patients who received an HCT for an
isolated extramedullary relapse had a signiﬁcantly lower rate
of post-HCT relapse compared with isolated/combined BM
patients (15% [95% CI, 5% to 28%] versus 45% [95% CI, 32% to
58%]; P < .001) (Figure 2A) and greater rates of DFS at 3 years
(56% [95% CI, 39% to 72%] versus 35% [95% CI, 23% to 47%];
P¼ .05) (Figure 2B). There was no difference in relapse or DFS
based on graft source (Figure 3A,B). The remaining variables
tested in univariate analysis, including age at HCT, perfor-
mance score, CMV status, donorerecipient HLA match, and
presentingWBC count and time period of HCT (2000 to 2003
versus 2004 to 2007 versus 2008 to 2011), were not signiﬁ-
cant for any outcome measure.
In multivariable analysis (Table 3), only the site of ﬁrst
relapse, either isolated BM or combined BM and extra-
medullary disease, was strongly predictive of a subsequent
relapse post-HCT (hazard ratio, 3.94; 95% CI, 1.51 to 10.25;
P ¼ .005) as compared with isolated extramedullary disease.
The effect of GVHD on relapse was not statistically signiﬁcant
for either acute GVHD (P ¼ .51) or chronic GVHD (P ¼ .33). No
other patient, disease, or treatment variables were signiﬁ-
cant when tested in multivariable analysis, including time
from diagnosis to HCT (<18 months versus >18 months).
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Figure 3. (A) Cumulative incidence of relapse at 3 years for patients receiving
HLA-matched sibling BM was 34% (95% CI, 24% to 45%), unrelated BM/PBSCs
was 34% (95% CI, 23% to 46%), and unrelated UCB was 24% (95% CI, 15% to 34%)
(P ¼ .26). (B) Probability of DFS at 3 years for patients receiving HLA-matched
sibling BM was 48% (95% CI, 37% to 59%), unrelated BM/PBSCs was 37% (95% CI,
25% to 49%), and unrelated UCB was 50% (95% CI, 39% to 61%) (P ¼ .25).
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Children with relapsed T-ALL treated with chemotherapy
alone have done poorly with OS rates of <20% regardless of
the duration of CR1 [14,15,25-27]. As a result of poor out-
comes with chemotherapy, HCT is often considered the
standard of care for patients with relapsed T-ALL with either
a BM relapse or isolated extramedullary relapse [28], despite
the lack of publications regarding HCT-speciﬁc outcomes for
relapsed pediatric T-ALL. However, a comparison of out-
comes for children with relapsed T-ALL receiving chemo-
therapy alone versus HCT may be biased by the fact that
many of these patients are not able to attain sufﬁcient dis-
ease control to proceed to HCT.
Although HCT for relapsed T-ALL has produced durable
remissions, there are limited data describing outcomes for
these patients. The vast majority of literature supportingTable 3
Multivariate Analysis of Risk of Post-HCT Relapse
Site of ﬁrst relapse N Hazard Ratio (95% CI) P*
Isolated CNS or testes 34 1.00
Isolated BM/combined BM 65 3.94 (1.51-10.25) .005
Not reported 125 2.28 (.89-5.83) .08
CNS indicates central nervous system.
Other comparisons: site of ﬁrst relapse not reported vs BM  other was .58
(.35-.96), P ¼ .03. The effect of GVHD on relapse was not statistically sig-
niﬁcant: grades II-IV acute GVHD (P ¼ .51) and chronic GVHD (P ¼ .33).
* Overall P ¼ .008.transplantation in childhood ALL combines T-ALL data with
B cell ALL, limiting the ability to distinguish the outcomes for
T-ALL [14]. One publication focused on HCT outcomes for
T-ALL in adolescents and adults who received a myeloa-
blative HCT, most of whom were in CR1 (60%). The median
patient agewas 18 years, with most patients (68%) aged 14 to
20 years [16]. Patients who received HCT in at least CR2
(n ¼ 18) had a TRM of 32% and a relapse rate of 35%. The
authors found that 5-year OS was best for those transplanted
in CR1 (54%; n ¼ 32) compared to an OS rate of 32% for those
in CR2 or greater at the time of HCT [16]. Although these
results may be less applicable to our strictly pediatric pop-
ulation, the outcomes are comparable with our results,
which report 3-year rates for TRM, relapse, and OS of 24%,
30%, and 48%, respectively.
The improved outcomes with HCT versus chemotherapy
alone in relapsed ALL patients are thought to be in part
related to a graft-versus-leukemia (GVL) effect. The presence
of GVHD is often used as a surrogate for GVL, because several
publications have demonstrated that patients with GVHD
have lower relapse rates [29,30]. Our ﬁnding that neither
acute nor chronic GVHD impacted relapse raises the question
as to how signiﬁcant the GVL effect is in pediatric patients
with relapsed T-ALL in CR2. It is possible that the GVL effect is
only seen in lower grades of acute GVHD, such as in I to II or II
to III versus III to IV or IV alone, where the latter groups are
more likely to be associated with TRM and thus losing any
appreciable GVL effect. Given our relatively small cohort, we
were unable to test this hypothesis. Additional studies are
needed to further understand the role, if any, of GVL in T-ALL.
We found that patients with a BM relapse  extra-
medullary disease were almost 4 times as likely to relapse
post-HCT compared with those patients with an isolated
extramedullary relapse. This would suggest that isolated
extramedullary T-ALL relapse may be a lower risk disease (as
is the case for isolated extramedullary relapse in B cell ALL)
compared with relapses that include BM involvement.
Identifying a signiﬁcantly higher risk group provides an op-
portunity to develop more novel approaches to improve
transplant outcomes in this patient population.
Because of the limitations of a retrospective registry-
based analysis, we were unable to include prior treatment
history (eg, nelarabine), disease immunophenotyping (eg,
early T cell progenitor T-ALL), or measurements of pre-HCT
minimal residual disease. These are admittedly important
aspects to determining the outcomes of HCT in this popula-
tion, and we would advocate for their future inclusion in
CIBMTR-based data collection. As well, registry-based
studies can have biases due to data collection and patient
ascertainment.
We identiﬁed that patients with an initial relapse site of
BM  extra medullary disease have signiﬁcantly inferior
survival. However, we did not ﬁnd outcome associations
with patient age at HCT, gender, presence of acute or chronic
GVHD, CMV status, TBI  or <1300 cGY, time from initial
diagnosis to transplant, the year in which patients received
their HCT, or whether or not they received serotherapy.
Importantly, there was no difference in relapse or DFS rates
based on graft source; therefore, when considering HCT for
relapsed T-ALL, transplant from the best available donor
should be offered in suitable patients.
In summary, we report the largest series of pediatric
transplant outcomes for patients with relapsed T-ALL in CR2
with a 3-year survival rate approaching 50%. These results
are encouraging and appear to be durable, particularly when
M.J. Burke et al. / Biol Blood Marrow Transplant 21 (2015) 2154e2159 2159compared with chemotherapy alone for relapse T-ALL where
survival is <20%, providing further evidence to support the
role of transplant in these patients. Based on these data,
consideration for HCT for T-ALL in CR2 is warranted.
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